References
1. Callaway E. Heavily mutated Omicron variant puts scientists on
alert[J]. Nature,2021,600(7887):21.
2. ZHONG Z, ZHANG Q, XIA H, et al. Clinical characteristics and
immunosuppressant management of coronavirus disease 2019 in solid organ
transplant recipients[J]. Am J Transplant, 2020, 20(7):1916-1921.
3. TAHA M, SHARMA A, TAHA M, et al. Coronavirus disease 2019 in
immunocompromised organ transplant recipients: a case report and review
of the literature[J]. Transplant Proc, 2020, 52(9):2698-2702.
4. MOHAMMED AH, BLEBIL A, DUJAILI J, et al. The risk and impact of
COVID-19 pandemic on immunosuppressed patients: cancer, HIV, and solid
organ transplant recipients[J]. AIDS Rev, 2020, 22(3):151-157.
5. YI SG, ROGERS AW, SAHARIA A, et al. Early experience with COVID-19
and solid organ transplantation at a us high-volume transplant
center[J].Transplantation, 2020, 104(11):2208-2214.
6. NIMMO A, GARDINER D, USHIRO-LUMB I, et al. The global impact of
COVID-19 on solid organ transplantation: two years into a
pandemic[J]. Transplantation, 2022, 106(7):1312-1329.
7. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney
transplantation[J]. N Engl J Med, 2020, 382(25): 2475-2477.
8. Columbia University Kidney Transplant Program. Early description of
coronavirus 2019 disease in kidney transplant recipients in New York [
J ] . J Am Soc Nephrol ,2020, 31(6): 1150-1156.
9. Ao G, Wang Y, Qi X et al. The association between severe or death
COVID-19 and solid organ transplantation: a systematic review and
meta-analysis. Transplant Rev (Orlando) 2021(35): 100628.
10. RAJA MA, MENDOZA MA, VILLAVICENCIO A, et al. COVID-19 in solid organ
transplant recipients: a systematic review and meta-analysis of current
literature[J]. Transplant Rev (Orlando), 2021, 35(1):100588.
11. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of
humanized recombinant anti–interleukin‐6 receptor antibody in children
with systemic‐onset juvenile idiopathic arthritis[J]. Arthritis &
Rheumatism, 2005, 52(3): 818-825.
12. Piechotta V , Chai K L , Valk S J , et al. Convalescent plasma or
hyperimmune immunoglobulin for people with COVID: a living systematic
review[J]. Cohrane Database of Systematic Reviews, 2020, 10(10).
13. Jayk Bernal A, Gomes da Silva MM, Musungaie DB et al. Molnupiravir
for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med
2021; 386: 509–20.
14. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for
highrisk, nonhospitalized adults with covid-19. N Engl J Med 2022; 386:
1397– 408.
15. Gottlieb RL, Vaca CE, Paredes R et al. Early remdesivir to prevent
progression to severe covid-19 in outpatients. N Engl J Med 2021; 386:
305–315.
16. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment
of Covid-19—final report. N Engl J Med. 2020;383:1813–1826.
17. Loo Y M , Mctamney P M , Arends R H , et al. AZD7442 demonstrates
prophylactic and therapeutic efficacy in non-human primates and extended
half-life in humans[J]. 2021.
18. Hammitt L L, Dagan R, Yuan Y, et al. Nirsevimab for prevention of
RSV in healthy late-preterm and term infants[J]. New England Journal
of Medicine, 2022, 386(9): 837-846.
19.Chaplin S . Paxlovid: antiviral combination for the treatment of
COVID‐19[J]. Prescriber, 2022, 33(3-4):31-33.
20. KREMER D, PIETERS TT, VERHAAR MC, et al. A systematic review and
meta-analysis of COVID-19 in kidney transplant recipients: lessons to be
learned[J]. Am J Transplant, 2021,21(12):3936-3945.
21. JAYANT K, RECCIA I, VIRDIS F, et al. COVID-19 in hospitalized liver
transplant recipients: an early systematic review and
meta-analysis[J]. Clin Transplant, 2021,35(4):e14246.
22. DUARSA GWK, SUGIANTO R, YUSARI IGAAA, et al. Predictor factor for
worse outcomes in kidney transplant recipients infected with coronavirus
disease 2019: a systematic review and meta-analysis[J]. Transpl
Immunol, 2023,76:101739.
23. LIU H, HE X, WANG Y, et al. Management of COVID-19 in patients after
liver transplantation: Beijing working party for liver
transplantation[J]. Hepatol Int, 2020,14(4):432-436.